Welcome to the 2021 IGCS Meeting Program Scheduling
The meeting will officially run on Central European Time (Rome time-zone, GMT+2)
To convert the meeting times to your local time Click Here
Hall 1
Session Type
Master Session
Room
Hall 1
Date
08/30/2021
Chair(s)
Session Description
Session Description: This interactive and exciting session will feature international thought leaders in cervical cancer to discuss challenges in the current standard of care, from prevention to second-line and greater chemotherapy. The first half of the session will discuss the current status of HPV vaccination, the gap between cervical cancer incidence and eradication, and clinical dilemmas in stage allocation and surgery/radiation overlap for optimal patient management in low volume disease. The second half will discuss ongoing and resulted clinical trial that are ushering in a new era of immunotherapy for locally advanced and metastatic/recurrent cervical cancer.
This session is supported by Industry.
Master Session
Opening Comments (ID 707)
Lecture Time
04:45 PM - 04:50 PM
Presenter
Master Session
Case #1: Prevention & Staging (ID 708)
Lecture Time
04:50 PM - 04:53 PM
Presenter
Authors
Master Session
a) How do we get to eradication? b) Is”catch up vaccination “ worthy in older than teen-agers? Is it the soluction for “vulnerable economies”? (ID 709)
Master Session
Staging (ID 713)
Lecture Time
05:03 PM - 05:06 PM
Presenter
Authors
Master Session
a) PET/CT VS MRI to stage LRACC: PRO’S AND CON’S b) Should we rely on imaging for pre surgical staging? (ID 714)
Lecture Time
05:06 PM - 05:16 PM
Presenter
Authors
Master Session
Case #2: Surgery vs CCRT for LACC (ID 1016)
Lecture Time
05:16 PM - 05:18 PM
Presenter
Master Session
Pro Surgery (ID 1017)
Lecture Time
05:18 PM - 05:28 PM
Presenter
Authors
Master Session
Pro Radiation: In view of the results of the Abrax trial, should we operate clinically node positive pts? What method is most reliable? (ID 1018)
Lecture Time
05:28 PM - 05:38 PM
Master Session
Addition systemic therapy to radiation (CCRT) (ID 1019)
Lecture Time
05:38 PM - 05:41 PM
Presenter
Master Session
Current status of definitive LACC clinical trials (ID 1020)
Lecture Time
05:41 PM - 05:46 PM
Master Session
Case #3: Recurrent and Metastatic Disease 1L IO (ID 1021)
Lecture Time
05:46 PM - 05:49 PM
Master Session
Entering the Immunotherapy Era in Cervical Cancer: the seismic shift in the treatment landscape (ID 1022)
Master Session
Second-line metastatic disease case (ID 1023)
Lecture Time
05:59 PM - 06:02 PM
Master Session
Turn on the TV!: Getting to know the antibody drug conjugate, tisotumab vedotin (ID 1024)
Master Session
The new dilemma of biomarkers for ICI and sequencing therapies in cervical cancer (ID 1025)
Lecture Time
06:12 PM - 06:14 PM
Master Session
The new dilemma of biomarkers and sequencing IO and TV in cervical cancer (ID 1026)
Lecture Time
06:14 PM - 06:24 PM
Master Session
Q&A/discussion (ID 1027)
Lecture Time
06:24 PM - 06:42 PM
Master Session
Wrap Up (ID 1028)
Lecture Time
06:42 PM - 06:45 PM